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Leptin, and Ghrelin before and after Weight Loss
Induced by Gastric Bypass Surgery in Morbidly
Obese Subjects
MAY FARAJ, PETER J. HAVEL, STEVE PHE´LIS, DAVID BLANK, ALLAN D. SNIDERMAN, AND
KATHERINE CIANFLONE
Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University (M.F., S.P., A.D.S., K.C.), and Division of
Clinical Biochemistry, Royal Victoria Hospital (D.B.), Montre´al, Que´bec, Canada; and Department of Nutrition, University
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We examined fasting plasma insulin, acylation-stimulating
protein (ASP), leptin, adiponectin, ghrelin, and metabolic/car-
diovascular risk profile before and 15  6 months after iso-
lated Roux-en-Y gastric bypass surgery in 50 morbidly obese
subjects. Average preoperative plasma lipids were mostly nor-
mal, whereas ASP, insulin, and leptin were elevated, and adi-
ponectin and ghrelin were decreased. Postoperatively, body
weight decreased significantly (36.4  9.6%) and was best
predicted by preoperative adiponectin concentration in
weight-stable subjects (r0.59; P 0.02). Plasma lipids and
insulin resistance improved, leptin and ASP decreased
(76.3  14.6% and 35.9  52.2%; P < 0.001), and adiponectin
increased (50.1  47.0%; P < 0.001). The decrease in apoli-
poprotein B was best predicted by the decrease in ASP (r 
0.55; P  0.009), whereas the improved postoperative insulin
sensitivity was best predicted by the increase in adiponectin
(r  0.70; P  0.01). Despite bypassing 95% of the stomach and
isolating the fundus from contact with ingested nutrients,
circulating ghrelin did not decrease after surgery. In fact,
plasma ghrelin increased postoperatively in the subset of sub-
jects undergoing active weight loss (60.5 23.2%; P < 0.001);
ghrelin, however, remained unchanged in weight-stable sub-
jects. In summary, 1) preoperative adiponectin concentra-
tions may be predictive of the extent of weight loss; 2) changes
in ASP and adiponectin are predictive of decreased apoli-
poprotein B and improved insulin action, respectively; and 3)
plasma ghrelin increases after gastric bypass surgery in pa-
tients experiencing active weight loss. (J Clin Endocrinol
Metab 88: 1594–1602, 2003)
OBESITY HAS BECOME an epidemic in affluent societ-ies. Cohort and cross-sectional studies have shown
that obesity is associated with coronary artery disease, dia-
betes, and hypertension (1). Obesity is an inevitable conse-
quence of chronic positive energy balance. The regulation of
energy balance between intake and expenditure and the sub-
sequent metabolic profile that evolves during positive en-
ergy balance are mediated by a complex network of signals
originating from a number of endocrine tissues, including
pancreas, adipose tissue (2), and, as recently discovered,
stomach (3). These peripheral signals are integrated in the
central nervous system (primarily in the hypothalamus) in
the regulation of energy intake and expenditure (4, 5).
Adipose tissue synthesizes and secretes a number of cy-
tokine hormones that are involved in the regulation of energy
homeostasis, insulin action, and lipid metabolism (6). Acy-
lation-stimulating protein (ASP), which is identical to
C3adesarg, is a lipogenic adipocytokine whose precursors,
complement C3, adipsin, and factor B, are synthesized and
secreted by adipose tissue in a differentiation-dependent
manner (7, 8). ASP is linked to the pathogenesis of obesity via
its action to enhance triglyceride synthesis and storage in the
adipocyte. ASP increases both glucose uptake as well as fatty
acid esterification in a manner that is independent of but
additive to insulin (9). Mice with a genetic knockout of C3,
which are unable to produce ASP, are resistant to diet-
induced obesity and insulin resistance (10). The concentra-
tion of ASP is elevated in obesity (11), type II diabetes mel-
litus (12), and coronary artery disease (13). Weight loss in
obese subjects induced by fasting (14) or hypocaloric diets
(15) decreases the concentration of plasma ASP.
Leptin, the product of the ob gene, is also an adipocytokine
secreted by white adipose tissue (16). Originally leptin was
proposed to act as a signal indicating abundant adipose
stores to the hypothalamus to limit energy intake and in-
crease energy expenditure (17). Subsequently, it has been
suggested that the primary role of leptin is in adaptation to
negative energy balance (18, 19). Accordingly, decreases in
circulating leptin are associated with increased hunger (20),
and leptin replacement prevents the compensatory decrease
in metabolic rate and thyroid axis function after diet-induced
weight loss in humans (21). Furthermore, there is some ev-
idence linking leptin to a direct regulation of adipose tissue
metabolism through inhibition of lipogenesis and stimula-
tion of lipolysis (22, 23). Circulating leptin concentrations are
elevated in obesity and decrease after weight loss (24).
Adiponectin, is one of the most abundant adipose tissue-
specific factors (25, 26). Recent data suggest that adiponectin
Abbreviations: apoB, Apolipoprotein B; ASP, acylation-stimulating
protein; BMI, body mass index; HDL, high density lipoprotein; HOMA-
IR, homeostasis model assessment for insulin resistance; LDL, low den-
sity lipoprotein; NEFA, nonesterified fatty acids; TG, triglycerides.
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is a mediator of insulin sensitivity and an enhancer of fatty
acid oxidation (27). In contrast to ASP and leptin, plasma
levels of adiponectin are lower in obese subjects, and the low
levels are associated with risk factors for coronary artery
disease (28, 29) and insulin resistance (30, 31). Low levels of
adiponectin are also associated with the reduced ability of
insulin to phosphorylate insulin receptor tyrosine residues
and are predictive of the development of insulin resistance
in humans (32). Administration of adiponectin to rodents
increases insulin sensitivity, an action that appears to result
from lowered hepatic glucose production and increased
muscle fatty acid oxidation (33), and adiponectin knockout
mice exhibit insulin resistance (33, 34). Circulating adiponec-
tin concentrations have been reported to increase after
weight loss (35).
Ghrelin is a recently described hormone predominantly pro-
duced by the stomach fundus that acts on GH secretagogue
receptors to increase GH release from the pituitary gland (36).
Ghrelin administration increases food intake, decreases fat ox-
idation, increases adiposity in rodents (37), and triggers hunger
and increased food intake in humans (38). Circulating ghrelin
levels are suppressed by meal ingestion or intragastric glucose
administration, but not gastric distension, and rise during fast-
ing (3, 39). Plasma ghrelin concentrations are reduced in obese
subjects (39), and diet-induced weight loss increases circulating
ghrelin concentrations (40, 41).
Isolated longitudinal Roux-en-Y gastric bypass surgery is
a procedure used to treat morbid obesity [body mass index
(BMI),40 kg/m2] by restricting the volume of the stomach
available for use to less than 15 ml and bypassing a subsec-
tion of the small intestine (42, 43). Weight loss after gastric
bypass surgery is known to result from decreased energy
intake rather than nutrient malabsorption (42). Although the
mechanism(s) by which gastric bypass surgery induces long-
term weight loss, often without increases in hunger, are not
well understood, it has recently been hypothesized that re-
ductions of circulating ghrelin may contribute to the success
of weight loss after bypass surgery (41).
ASP, adiponectin, leptin, and ghrelin are all involved in
the regulation of energy homeostasis and have been exam-
ined separately in relation to obesity and moderate weight
loss. However, the complementary roles that these hormones
may have in long-term regulation of energy balance have not
been examined in the same population of morbidly obese
subjects under weight-stable conditions and during dynamic
weight loss. In addition, in studies examining ASP and
ghrelin concentrations after gastric bypass surgery, only
postgastric bypass values have been presented (41, 44). The
aim of this study was therefore to examine plasma ASP,
adiponectin, leptin, ghrelin, and metabolic/cardiovascular
risk profile (i.e. glucose, insulin, and lipid parameters) before
and after massive weight loss induced by gastric bypass
surgery in morbidly obese subjects. As adipose tissue plays
an active role in the regulation of energy balance and nutrient
metabolism, we hypothesized that preoperative levels of the
adipose tissue hormones ASP, leptin, and adiponectin would
be predictive of the extent of weight loss, and that changes
in these hormones would predict improved metabolic/
cardiovascular profile after weight loss.
Subjects and Methods
Study subjects
Fifty morbidly obese subjects (39 women and 11 men) underwent
standardized isolated longitudinal Roux-en-Y gastric bypass surgery for
the treatment of obesity at the Royal Victoria Hospital by two surgeons.
Detailed descriptions of the surgical procedures have been previously
published (42, 43). In brief, a small longitudinal 4- to 8-cm long gastric
pouch, 1.5 cm in diameter (15 ml), is created along the lesser curvature
of the stomach. The jejunum is divided 100 cm distal to the ligament of
Treitz and advanced in a retrocolic/retrogastric position to create a
100-cm Roux-en-Y limb, which is anastomosed to the gastric pouch. The
gastric pouch-jejunal anastomosis is 1–1.2 cm in diameter (around an
18-gauge naso-gastric tube).
Pre- and postoperative anthropometric measurements (weight and
height) were made, and blood samples were collected at the Obesity
Clinic where patients were followed at a decreasing frequency six times
during the first year after the surgery and semiannually thereafter (an
average of 6  2 times/patient in this study). Postoperative weight and
plasma values reported here correspond to those collected during the
last visit, 15  6 months after the surgery. Information regarding pa-
tients’ anthropometric measurements, medical history, surgery details,
and medication used were collected from the patients’ hospital charts.
Surgery details regarding gastric pouch size, length of the bypassed
intestine, and gastrojejunostomy diameter were collected from the pa-
tient’s operation report. Patients were excluded if they had reported
symptomatic coronary artery disease, were taking lipid-lowering drugs,
or were less than 6 months postsurgery at the time of data collection.
Postoperatively, patients were classified as either weight stable (neutral
energy balance) or weight reducing (negative energy balance). Weight
stability was defined as weight loss of less than 10% over the 6-month
period preceding the final measurement (average, 1.7% weight loss/
month) (45). All subjects had signed a written consent to the study,
which was approved by the research ethics board of the Royal Victoria
Hospital.
Plasma lipids, apolipoprotein B (apoB), and
glucose concentrations
Pre- and postoperative blood samples were collected for all 50 sub-
jects for the measurement of 12 plasma parameters of interest. Due to the
lack of sufficient sample volume for some subjects at the time of data
analysis, some plasma parameters could not be measured for all subjects.
The number of subjects for whom data were available for each parameter
is indicated in Table 1 or Figs. 1 and 2.
Venous blood samples (10 ml) were collected after an overnight fast
in tubes containing EDTA and were immediately centrifuged at 1500
rpm for 15 min at 4 C. Plasma samples were frozen at –80 C for later
measurement of lipids, apoB, glucose, insulin, leptin, ASP, adiponectin,
and ghrelin. Plasma triglycerides (TG) and nonesterified fatty acids
(NEFA) were measured by commercial enzymatic colorimetric kits
(Roche, Laval, Canada). High density lipoprotein (HDL) cholesterol was
separated according to the method described by Gidez et al. (46) by
heparin/manganese chloride precipitation (Sigma-Aldrich, St. Louis,
MO). Total and HDL cholesterol were measured using a commercial
enzymatic colorimetric kit (Roche). Low density lipoprotein (LDL) cho-
lesterol was calculated according to Friedewald’s equation (47): LDL
cholesterol  total cholesterol – HDL cholesterol – (TG/2.2), where all
values are in millimolar concentrations, except when plasma TG ex-
ceeded 4.6 mm. ApoB was measured by a commercial nephelometric
assay using Immage analyzer (Beckman-Coulter, Brea, CA). Plasma
glucose was measured using a 2000 STAT Plus analyzer (YSI, Inc.,
Yellow Springs, OH).
The normal concentration for NEFA was 0.100–0.800 mm for men and
women (48). The normal cut-off points for plasma TG and total, HDL,
and LDL cholesterol were set between the 25–75th percentiles of a
healthy North American population distribution with the same average
age (49). The normal concentration for plasma TG was between 0.75–1.31
mm for women and 1.00–1.96 mm for men. The normal concentrations
for total, HDL, and LDL cholesterol were 4.45–5.69, 1.24–1.68, and 2.69–
3.78 mm for women and 4.63–5.92, 0.93–1.32, and 2.97–4.06 mm for men,
respectively. The normal range for plasma apoB was set between the
25–75th percentile in the Framingham Offspring Study, which was
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93–111 mg/dl for women and 103–118 mg/dl for men (50). The
normal range for plasma glucose for men and women was between
2.5–5.3 mm (48).
Plasma ASP, insulin, leptin, adiponectin, and
ghrelin concentrations
Plasma ASP was assayed by an in-house ELISA using a monoclonal
antibody as capture antibody and a polyclonal antibody as detecting
antibody as described in detail previously (11, 51). A standard curve over
the range of 0.08–3.13 nm was prepared using purified plasma human
ASP. The plasma ASP level in obese subjects in this study was compared
with that in a reference nonobese Canadian population, which was
previously published by our group (23.5  10.8 nm) (11).
Plasma insulin, leptin, adiponectin, and ghrelin were all assayed by
standardized RIA kits. Insulin was measured with a human insulin-
specific RIA kit (Linco Research, Inc., St. Charles, MO) that does not react
with proinsulin. The normal range for plasma insulin was 4.9–24.3
U/ml for both men and women (48). Leptin was measured with a
standardized RIA kit (Linco Research, Inc.) using a 125I-iodinated human
leptin tracer as previously described (52). Standards over the range of
0.5–100 ng/ml were prepared using recombinant human leptin. Leptin
concentrations in normal weight subjects are 16.2  6.9 ng/ml for
women and 3.7  1.7 ng/ml for men (53). Plasma adiponectin levels
were measured using a standardized RIA kit for human adiponectin
(Linco Research, Inc.). The assay uses 125I-labeled adiponectin and an
antiadiponectin rabbit antiserum to determine adiponectin concentra-
tions by the double-antibody/polyethylene glycol technique. Standards
over the range of 1–200 ng/ml were prepared using recombinant human
adiponectin. All plasma samples were diluted 1:200, yielding an effec-
tive range of 0.2–40 g/ml. The intra- and interassay coefficients of
variation at adiponectin concentrations in the range of 3–15 g/ml are
1.8–6.2% and 6.9–9.3%, respectively. With this assay we measured
plasma adiponectin concentrations of 8.3  3.2 g/ml in 22 normal
weight healthy subjects (mean  sd; unpublished observations). For
ghrelin, a standardized RIA kit (Phoenix Pharmaceuticals, Inc., Belmont,
CA) was used with an antibody directed against the central portion of
the ghrelin molecule. The detection limits for the ghrelin RIA assay were
2.9–378.9 pm. The reference group value for plasma ghrelin concentra-
tions in normal weight subjects is 132.4  13.1 pm (39).
Homeostasis model assessment for insulin resistance
(HOMA-IR)
HOMA-IR was calculated from fasting plasma insulin and glucose
levels as (insulin  glucose)/22.5, where the insulin concentration is
reported as milliunits per liter and glucose as millimolar concentrations
(54). Thus, the normal range for HOMA-IR calculated from normal
ranges of insulin and glucose is 0.54–5.72 mU/litermm.
Statistical analysis
Parametric data were expressed as the mean  sd. Nonparametric
data were expressed as the median and 75th percentile. Data were
compared using paired t test (pre- vs. postoperative) and two-sample t
test (women vs. men, weight-stable vs. weight-reducing subjects) for
normal data or signed rank test and Mann-Whitney rank-sum test for
nonparametric data. Correlation was analyzed by the Pearson product-
moment correlation for parametric and Spearman rank test correlation
for nonparametric variables, and regression was analyzed by forward
stepwise regression. Correlation and regression analyses were con-
ducted for weight-stable subjects only. Statistical analysis was per-
formed using SigmaStat (Jandel, San Rafael, CA), with significance set
at P  0.05 and a power of more than 80%.
Results
Body weight, plasma lipids, and apoB
As many of the metabolic parameters studied may be
regulated by nutritional status, subjects were separated into
two groups based on postoperative weight stability (Table 1).
The gender differences in the pre- or postoperative states
were not significant; thus, data from women and men were
pooled (gender differences are reported for each parameter
where they are significant).
The average preoperative BMI was 50.2  8.1 kg/m2 in
women (n 39) and 50.7 14.9 kg/m2 in men (n 11). BMI
was dramatically reduced after surgery (16–55% weight
lost), and seven subjects in the weight-stable and four in the
weight-reducing groups attained ideal body weight (BMI,
20–25 kg/m2). However, despite massive weight loss (50
kg on the average in both groups), most subjects were still
categorized as obese, and to a comparable degree in both
weight-stable and weight-reducing groups (52% and 64%
above BMI 30 kg/m2, respectively).
Preoperative elevated plasma TG was the most frequent
lipid abnormality occurring in 49% of women (1.31 mm)
and 36% of men (1.96 mm), followed by low plasma HDL
cholesterol, occurring in 44% of women (1.24 mm) and 36%
TABLE 1. Pre- and postoperative characteristics in weight-stable and weight-reducing subjects
Weight-stable (n  25, 18 women) Weight-reducing (n  25, 21 women)
Preoperative Postoperative % Change Preoperative Postoperative % Change
Age (yr) 42  9 43  10 39.4  7 40  7
Duration (months) 17.5  4.9a 12.3  5.7
Weight (kg) 134.6  26.8 85.6  17.6b 35.9  10.0 139.3  31.9 87.4  21.1b 37.0  9.3
BMI (kg/m2) 48.5  10.1 30.7  6.1b 35.9  10.0 52.0  9.3 32.6  6.6b 37.0  9.3
% Weight loss/month 0.5  0.6a 3.4  1.4
TG (mM) 1.25 (1.66) 0.83 (1.12)b 30.1  25. 1.44 (1.93) 0.82 (1.03)b 39.3  21.8
NEFA (mM) 0.377  0.155 0.321  0.163 3.6  62.4 0.393  0.159 0.321  0.239 8.9  65.1
T-CHOL (mM) 4.79  0.84 4.06  0.64b 14.2  12.2 5.13  0.92 3.91  0.82b 22.6  17.5
HDLC (mM) 1.24  0.38 1.13  0.45a 5.7  30.8 1.04  0.35 0.82  0.30c 11.9  45.5
LDLC (mM) 3.43  0.85 2.57  0.66b 22.2  22.0 3.92  0.92 2.68  0.78b 29.5  22.7
apoB (mg/dl) 111.0  47.6 70.8  14.7b 26.6  23.2 117.5  36.5 75.5  20.7b 30.1  23.9
Glucose (mM) 5.64 (8.58) 4.36 (4.68)c 23.0  21.4 5.24 (6.00) 3.69 (4.01)b 33.9  23.5
Insulin (U/ml) 27.2 (31.8) 11.7 (12.5)b 33.4  37.5 25.6 (36.2) 10.1 (12.7)b 52.7  18.6
HOMA-IR 7.76 (9.52) 1.92 (2.57)b 55.3  26.2 7.80 (10.23) 1.69 (2.05)b 72.4  13.3
T-CHOL, Total cholesterol; HDLC, HDL cholesterol; LDLC, LDL cholesterol. All data are presented as mean SD, except for nonparametric
values; TG, glucose, insulin, and HOMA-IR are presented as median (75th percentile). For insulin, glucose, and HOMA-IR, n  13 in
weight-stable and n  17 in weight-reducing subjects.
a P  0.05 weight-reducing vs. weight-stable subjects; b P  0.001 and c P  0.05 post- vs. preoperative values.
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of men (0.93 mm). Yet despite those lipid abnormalities in
some subjects, preoperative median TG and average total
and LDL cholesterol were all within the normal range for
both women and men. Preoperative mean HDL cholesterol
in women (1.14  0.39 mm) was, however, lower than the
normal range. None of the patients studied had abnormal
preoperative plasma NEFA; however, women had higher
preoperative NEFA than men (mean, 0.417  0.154 mm in
women vs. 0.272  0.107 mm in men; P  0.05). Postopera-
tively, median TG and average total, LDL, and HDL (in men)
cholesterol were all within the normal range. However,
plasma HDL cholesterol remained low in both weight-
reducing and weight-stable women (Table 1).
Preoperatively, plasma apoB was above the 75th percentile
in 38% of patients (16 women and 3 men), 16 of whom had
other lipid abnormalities, yet, on the average, it was normal
in both genders. Abnormal plasma apoB was the only lipid
parameter that was fully corrected after weight loss in all
subjects with elevated preoperative values despite their re-
maining obese on average.
Plasma glucose and insulin
Mean plasma glucose levels were slightly increased before
the bypass surgery. Preoperatively, 57% of the patients had
HOMA-IR levels above the upper limit for the calculated
normal range. Postoperatively, both glucose and insulin lev-
els decreased significantly with weight loss, and all patients
had HOMA-IR values within the normal calculated range
(Table 1). Subjects who were receiving medical treatment for
diabetes before the surgery (six women and four men) had
discontinued all hypoglycemic agents.
Plasma ASP, leptin, adiponectin, and ghrelin
Most obese subjects (86%) had elevated preoperative
plasma ASP concentrations (23.5  10.8 nm), with an av-
erage of 75.0 44.2 nm in women and 55.4 34.5 nm in men
(gender difference not significant; Fig. 1A). Postoperatively,
plasma ASP decreased in most subjects. However, the
average ASP concentrations in both weight-stable (31.4 
19.8 nm) and weight-reducing (35.5 22.5 nm) subjects were
still higher than normal (P  0.001 for both groups), consis-
FIG. 1. Pre- to postoperative changes in plasma ASP, leptin, adiponectin, and ghrelin after weight loss in weight-stable and reducing subjects.
The box represents the average  1 SD for a healthy lean reference group for each hormone (see Subjects and Methods; except for leptin where
the box represents average  SD for women only). Arrows indicate the average value for each hormone in the pre- and postoperative states in
this study. Women are shown by solid lines, and men are indicated by dotted lines. *, P  0.01; **, P  0.001 (post- vs. preoperative values).
a, P  0.04 (weight-stable vs. weight-reducing postoperative ghrelin concentrations).
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tent with the observation that most subjects in both groups
were still obese (BMI, 30 kg/m2).
Gender differences in plasma hormones were observed for
leptin concentrations only. Women had significantly higher
leptin in both preoperative (48.9  19.3 ng/ml in women vs.
27.6 24.4 ng/ml in men) and postoperative (11.1 8.3 ng/ml
in women vs. 5.1 2.9 ng/ml in men) states. Leptin decreased
postoperatively in almost all subjects (Fig. 1B), and in weight-
reducing women fell below normal reference values despite
the fact that the subjects remained obese (9.9  6.4 ng/ml in
postobese vs. 16.2  6.9 ng/ml in reference group; P  0.01).
These low leptin levels, despite increased fat mass, are consis-
tent with the known adiposity-independent effects of negative
energy balance on leptin production (2).
Mean preoperative adiponectin concentrations were lower
than those in the lean reference group (8.3 3.2 g/ml) in
both women (4.85 2.18 g/ml; P 0.001) and men (4.09
2.21 g/ml; P  0.02), and there were no significant gender
differences. In contrast to the other adipose tissue hormones
(ASP and leptin), adiponectin increased in response to
weight loss after gastric bypass surgery in almost all subjects
(Fig. 1C). Mean adiponectin was comparable to normal ref-
erence values in weight-stable and reducing subjects at 6.9
2.18 and 6.2  2.2 g/ml, respectively.
Before surgery, all obese subjects had low plasma ghrelin
concentrations compared with reference values in normal
weight subjects (119.3 pm), and there was no significant
gender difference (48.4 13.6 pm in women and 40.1 16.9
pm in men; P  NS; Fig. 1D). Despite bypassing most of the
stomach (95%) and completely isolating the fundus from
contact with nutrients, ghrelin concentrations did not de-
crease after surgery. Plasma ghrelin levels remained un-
changed in the weight-stable subjects, but increased by ap-
proximately 60% in weight-reducing subjects (i.e. those in
negative energy balance). Thus, the postoperative average
ghrelin level in the weight-reducing group was higher than
that in weight-stable subjects (80.8 27.7 vs. 54.2 15.8 pm;
P  0.04) despite the fact that their average postoperative
BMI and gastric pouch size were similar to those in weight-
stable subjects. Only one man in the weight-reducing group
(who achieved a postsurgery body weight/BMI within the
normal range) attained a plasma ghrelin concentration
FIG. 2. Regression and correlation analyses in weight-stable subjects. The regression analysis is between preoperative plasma adiponectin
concentration and percent drop in body weight (A), changes in plasma ASP and apoB concentrations (B), and changes in adiponectin and
postoperative HOMA-IR (C). D, Correlation analysis between postoperative ASP and leptin concentrations in weight-stable subjects.
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within normal limits for nonobese subjects (119.3–145.5 pm).
It should be noted, however, that all pre- and postoperative
ghrelin levels measured were well within the detection limits
of the ghrelin assay (2.9–378.9 pm).
Correlation analysis
Before surgery, the plasma parameters that correlated with
BMI were leptin (r  0.60; P  0.0005), HOMA-IR (r  0.50;
P 0.003), and plasma insulin (r 0.38; P 0.03). There was
a positive correlation between plasma insulin and leptin (r
0.35; P 0.04) and a negative correlation between HOMA-IR
and plasma ghrelin concentrations (r0.47; P 0.05). The
age of the subjects was correlated positively with plasma
adiponectin (r  0.39; P  0.03) and glucose (r  0.38; P 
0.04) and negatively with insulin concentrations (r  0.35;
P  0.04). There was no association between any of the
preoperative hormone levels and the metabolic parameters
examined other than that between HOMA-IR and TG (r 
0.37; P  0.03).
Postoperatively, there was a positive correlation between
the preoperative value and the postoperative change in every
plasma parameter measured; the higher the preoperative
concentration, the greater the postoperative decrease (data
not shown), except for adiponectin and ghrelin. The preop-
erative adiponectin level was negatively correlated with its
percent increase after surgery (r0.59; P 0.02), whereas
no such correlation was observed for changes in plasma
ghrelin levels.
As leptin, ASP, and adiponectin are all adipose tissue se-
creted factors, we examined the hypothesis that the preopera-
tive concentrations of these hormones are predictive of the
extent of weight loss in weight-stable subjects. Neither preop-
erative plasma leptin nor ASP concentrations were predictive
of the extent of postsurgical weight loss. However, although
adiponectin did not correlate with weight in the pre- or post-
operative states, by forward stepwise regression analysis, pro-
portional weight loss was best predicted by preoperative adi-
ponectin concentrations (r0.59; P 0.02). Thus, the lower
the preoperative plasma adiponectin level, the greater the per-
cent reduction in body weight (Fig. 2A).
We also examined whether changes in adipose tissue hor-
mone levels would be predictive of improved lipid profiles
and insulin sensitivity after weight loss in weight-stable sub-
jects. The decrease in apoB was best predicted by the decrease
in ASP, whereas changes in adiponectin and leptin did not
add any further predictive value to the changes in plasma
apoB. By regression analysis, 67% of the decrease in apoB
was predicted by the changes in ASP and TG, with ASP being
the primary predictor (55%; P  0.009; Fig. 2B). As for im-
proved insulin sensitivity postoperatively, 70% of post-
operative HOMA-IR values were predicted by the increase
in adiponectin (P  0.01), whereas in this model ASP and
leptin did not improve the prediction of postoperative
HOMA-IR. Thus, subjects who exhibited the greatest in-
crease in adiponectin concentrations were also the most in-
sulin sensitive in the postoperative state (i.e. lowest post-
operative HOMA-IR value; Fig. 2C). The extent of weight loss
also correlated with time since surgery (r  0.49; P  0.01)
and the changes in leptin (r  0.69; P  0.005), insulin (r 
0.62; P  0.02), and HOMA-IR (r  0.71; P  0.01).
In the postoperative state, leptin was the only hormone
that correlated with BMI after weight loss in weight-stable
subjects (r 0.62; P 0.001). An unexpected finding was the
negative correlation between postoperative plasma concen-
trations of ASP and leptin in weight-stable subjects (r 
0.43; P  0.04; Fig. 2D).
Discussion
Obesity is a complex metabolic state. In the present study,
despite the subjects’ pathological obesity, on the average,
preoperative lipid levels were surprisingly normal. The reg-
ulation of lipid metabolism and energy homeostasis in ex-
treme obesity is not well understood. However, along with
insulin, the four more recently described hormones exam-
ined in this study are believed to have major roles in substrate
metabolism and energy balance. Thus, we examined for the
first time all four hormones and their association with car-
diovascular risk factors in a population of morbidly obese
subjects before and after massive weight loss induced by
gastric bypass surgery.
The response of plasma lipids after surgery-induced
weight loss has been reported to be influenced by the type
of surgery performed, such as jejuno-ileal, biliopancreatic, or
gastric bypass (55–58). Therefore, only subjects who under-
went the same type of standardized surgery, isolated longi-
tudinal Roux-en-Y gastric bypass, were evaluated in the
present study. Isolated Roux-en-Y gastric bypass reduces the
volume of the stomach by about 95% and is associated with
reduced food intake (42). Although the mechanism(s) by
which this surgery produces substantial long-term weight
loss with decreased hunger and energy intake is not well
understood, persistent diarrhea, vomiting, and protein mal-
nutrition do not occur in these patients (43) nor is there any
evidence of fat malabsorption (44). The beneficial effects of
gastric bypass-induced weight loss on plasma lipids, insulin,
and glucose and the correction of diabetes have been dem-
onstrated by a number of studies (56, 59–63) as well as the
present report.
One major cardiovascular risk factor that few studies have
examined after gastric bypass-induced weight loss or in a
large sample size is plasma apoB. An elevated plasma apoB
concentration is an independent risk factor for ischemic heart
disease. Controlling for plasma TG, HDL cholesterol, and
total/HDL cholesterol ratios does not eliminate its signifi-
cance (64). In contrast to a previous study (63), abnormal
preoperative apoB concentrations were normalized after
weight loss in all subjects studied. Of note, the reductions in
plasma total and LDL cholesterol were relatively small com-
pared with that in apoB. Thus, assessment of changes in
plasma total and LDL cholesterol alone without examining
changes in apoB could minimize the true benefit of surgical
treatment of obesity in the reduction of cardiovascular dis-
ease risk factors.
We examined the hypothesis that the change in adipose
tissue hormones, ASP, leptin, and adiponectin, may predict
the amelioration of the metabolic/cardiovascular risk profile
after weight loss. The decrease in plasma ASP was the vari-
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able most predictive of the reduction of plasma apoB levels
after weight loss (55%). The close association between these
two variables may reflect the influence that fatty acid flux has
on both parameters. In a previous study fibroblasts obtained
from subjects with high plasma apoB and ASP concentra-
tions exhibited reduced glucose transport and triglyceride
synthesis capacity in response to stimulation with ASP (65).
This is consistent with ineffective adipose tissue fatty acid
trapping as TG and a net flux of fatty acids to the liver
resulting in high apoB. In the present study increased fatty
acid flux to the liver in obesity may result in hepatic apoB
overproduction (66), whereas increased fatty acid flux to
adipose tissue results in fat storage and increased ASP se-
cretion. Consequently, with caloric restriction, the reduced
ASP and apoB levels may reflect diversion of fatty acids for
energy demands, reducing both adipose storage and excess
hepatic lipoprotein secretion.
With respect to weight loss, preoperative plasma adi-
ponectin concentrations were predictive of the extent of
weight loss after bypass surgery. Lower preoperative adi-
ponectin concentrations predicted a greater percent reduc-
tion in body weight and were associated with greater in-
creases in plasma adiponectin concentrations after surgery.
In rodents, adiponectin administration decreases hepatic
glucose production and increases muscle fatty acid oxidation
(33, 67). Therefore, it is possible that those subjects with the
lowest preoperative adiponectin concentrations and who
had the greatest increase in adiponectin after weight loss may
have benefited from larger increases in muscle fatty acid
oxidation. The increase in adiponectin after weight loss was
also predictive of the improvement of insulin sensitivity as
estimated by HOMA-IR values. Interestingly, thiazolidinedi-
one (peroxisomal proliferator-activated receptor  agonists)
that improve insulin sensitivity in patients with type 2 dia-
betes also increase adiponectin gene expression and plasma
adiponectin levels (68), suggesting a mechanism by which
this class of drugs enhances insulin sensitivity. In addition to
improving insulin sensitivity, one of the demonstrated ef-
fects of adiponectin is the inhibition of TNF production and
TNF-induced monocyte adhesion to aortic endothelial cells,
an early stage in the atherosclerotic vascular change (69).
Obesity is associated with increased risk of both type II
diabetes and cardiovascular disease, thus increased adi-
ponectin production after weight loss in obese subjects may
represent an important link between weight loss and im-
proved insulin sensitivity and cardiovascular risk profiles.
ASP and leptin are also secreted by adipose tissue, but in
contrast to adiponectin, circulating levels of these hormones
tend to reflect the size of their tissue of origin, increasing with
obesity (2, 11). Before surgery, nearly all obese subjects had
elevated plasma ASP and leptin concentrations, and both
hormones decreased with postsurgical weight loss, although
the decreases in leptin were greater in magnitude. Despite
weight stability, there was no correlation between changes in
plasma ASP and weight loss. Similarly, although most
weight-stable subjects remained obese, all had normal or
below normal leptin concentrations compared with pub-
lished reference values, suggesting that factors other than
body adiposity regulate ASP and leptin production. Al-
though circulating leptin concentrations are highly corre-
lated with indexes of body adiposity, body fat mass is not the
sole determinant of plasma leptin levels (20, 53, 70–72), and
other nutritional factors, such as recent energy intake (53)
and dietary macronutrient composition (73), are involved in
the regulation of leptin production.
Two major determinants of circulating concentrations of the
novel gastroenteric hormone ghrelin have been identified. The
first is body weight, as plasma ghrelin concentrations are neg-
atively correlated with BMI over a wide range (74, 75). In this
study plasma ghrelin levels were indeed low in morbidly obese
subjects, although we did not observe a significant correlation
with BMI within this very obese population. The second factor
suggested to regulate ghrelin secretion is food intake, as plasma
ghrelin levels decrease shortly after food ingestion, a response
that may involve increases in circulating insulin and glucose
(39, 76) and/or contact of nutrients with the gastroenteric lumen
(37). Cummings et al. (41) recently reported that plasma ghrelin
concentrations over a 24-h period were markedly lower in five
patients studied after gastric bypass surgery than in either nor-
mal weight or comparably obese control subjects. Whether
plasma ghrelin was changed compared with its concentration
before surgery in that study is unknown, as presurgical ghrelin
levels were not measured in those patients. The researchers
hypothesized that ghrelin levels were low in these patients
because ingested nutrients bypassed most of the stomach and
upper intestine. They suggested that the paradoxical absence of
postprandial change in ghrelin, which is normally reduced by
food ingestion, was due to override inhibition from a contin-
uous empty stomach and duodenum. In agreement with these
results, in the present study plasma ghrelin concentrations after
surgery in weight-stable subjects remained low, comparably to
those reported by Cummings et al. (41).
However, plasma ghrelin levels increased by approximately
60% in the subset of subjects experiencing active weight loss at
the time the postsurgical samples were collected. In contrast,
plasma ghrelin did not increase after surgery in weight-stable
subjects (in neutral energy balance) despite a similar degree of
weight loss, postoperative BMI, and size of the gastric pouch as
in weight-reducing subjects (in negative energy balance). Thus,
energy balance may be a more important determinant of post-
surgical ghrelin levels after gastric bypass than body weight per
se. The postsurgical increase in ghrelin in weight-reducing sub-
jects suggests that ghrelin-secreting cells can increase the pro-
duction of ghrelin in response to negative energy balance, even
if the gastric fundus and upper small intestine are continuously
prevented from exposure to incoming nutrients. Alternatively,
the increase in ghrelin may reflect increased ghrelin secretion
from extragastric sources, as a number of other organs, includ-
ing much of the lower gastrointestinal tract, contain ghrelin and
could therefore contribute to circulating ghrelin levels (77).
Nonetheless, plasma ghrelin concentrations after surgery in
nearly all subjects, whether weight-stable or weight-reducing,
remained lower than the levels reported in either normal
weight or comparably obese subjects (41, 75). The finding that
plasma ghrelin is not increased after weight loss in weight-
stable patients contrasts with numerous reports that ghrelin
concentrations are substantially increased even after far lesser
degrees of weight loss produced by methods other than gastric
bypass surgery, i.e. calorie-restricted diets (40, 41). Thus, it is
possible that low circulating levels of this orexigenic hormone
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could contribute to initial weight loss and/or maintenance of
weight loss after this type of gastric bypass surgery.
The hormones examined (insulin, leptin, ghrelin, and ASP)
may be reciprocal indicators/regulators of acute and chronic
energy balance. Insulin and leptin have opposing actions to
ghrelin on food intake; leptin and insulin inhibit feeding,
whereas ghrelin is orexigenic. They are also opposing indi-
cators of chronic energy balance; circulating leptin and in-
sulin levels are increased in obesity and decrease with weight
loss, whereas the ghrelin concentration has opposite changes
(2, 3). Like leptin, plasma ASP is also elevated in obese
subjects and decreases after weight loss (11, 15), and although
there is little evidence for ASP action in the hypothalamus,
administration of ASP has been reported to acutely increase
short-term food intake in rodents (78). Improved insulin sen-
sitivity and sustained low ghrelin concentrations after gastric
bypass surgery would favor maintenance of weight loss in these
patients. In contrast, a combination of reduced postoperative
leptin and elevated ASP concentrations would favor increased
food intake, decreased energy expenditure, and increased ad-
ipose tissue fat storage and eventually promote weight regain
in postobese subjects. This subclass of patients with very low
leptin levels and high ASP concentrations might therefore be at
greater risk for postoperative weight regain.
In summary, weight loss is associated with amelioration
and often total correction of a number of the metabolic ab-
normalities associated with extreme obesity. Our results un-
derscore the coordinated roles of insulin, leptin, ASP, adi-
ponectin, and ghrelin as signals in the long-term regulation
of energy balance and carbohydrate and lipid metabolism.
Furthermore, in this study of isolated Roux-en-Y gastric by-
pass patients we report novel data suggesting that 1) pre-
operative fasting adiponectin concentrations are predictive
of the extent of weight loss; 2) changes in ASP and adiponec-
tin predict decreases in apoB and improved insulin action,
respectively; 3) plasma ghrelin concentrations increase after
bypass surgery in patients experiencing active weight loss
despite isolation of the fundus from incoming nutrients, but
remain low compared with those in normal weight subjects;
and 4) low ghrelin concentrations could contribute to de-
creased hunger and food intake, weight loss, and mainte-
nance of weight loss after gastric bypass surgery.
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